Campbell & Co Investment Adviser’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.34M | Sell |
23,327
-6,097
| -21% | -$350K | 0.07% | 452 |
|
|
2026
Q1 | $1.78M | Buy |
+29,424
| New | +$1.72M | 0.1% | 318 |
|
|
2025
Q4 | – | Sell |
-128,750
| Closed | -$5.81M | – | 1147 |
|
|
2025
Q3 | $5.81M | Buy |
128,750
+85,752
| +199% | +$4M | 0.44% | 17 |
|
|
2025
Q2 | $1.99M | Buy |
+42,998
| New | +$2.11M | 0.13% | 251 |
|
|
2024
Q3 | – | Sell |
-37,382
| Closed | -$1.55M | – | 1101 |
|
|
2024
Q2 | $1.55M | Buy |
37,382
+24,403
| +188% | +$1.09M | 0.13% | 230 |
|
|
2024
Q1 | $704K | Sell |
12,979
-5,341
| -29% | -$272K | 0.06% | 550 |
|
|
2023
Q4 | $940K | Sell |
18,320
-17,382
| -49% | -$912K | 0.08% | 415 |
|
|
2023
Q3 | $2.07M | Buy |
35,702
+28,823
| +419% | +$1.77M | 0.25% | 83 |
|
|
2023
Q2 | $440K | Buy |
6,879
+2,440
| +55% | +$164K | 0.08% | 496 |
|
|
2023
Q1 | $308K | Sell |
4,439
-7,927
| -64% | -$559K | 0.06% | 595 |
|
|
2022
Q4 | $890K | Sell |
12,366
-5,028
| -29% | -$379K | 0.21% | 127 |
|
|
2022
Q3 | $1.24M | Buy |
17,394
+6,278
| +56% | +$455K | 0.28% | 80 |
|
|
2022
Q2 | $856K | Buy |
11,116
+8,315
| +297% | +$633K | 0.23% | 110 |
|
|
2022
Q1 | $205K | Sell |
2,801
-2,099
| -43% | -$141K | 0.06% | 624 |
|
|
2021
Q4 | $306K | Buy |
+4,900
| New | +$287K | 0.1% | 352 |
|
|
2021
Q2 | – | Sell |
-12,264
| Closed | -$774K | – | 534 |
|
|
2021
Q1 | $774K | Buy |
+12,264
| New | +$763K | 0.48% | 40 |
|
|
2019
Q4 | – | Sell |
-8,656
| Closed | -$439K | – | 651 |
|
|
2019
Q3 | $439K | Buy |
+8,656
| New | +$407K | 0.17% | 223 |
|
|
2018
Q4 | – | Sell |
-5,577
| Closed | -$346K | – | 343 |
|
|
2018
Q3 | $346K | Buy |
+5,577
| New | +$331K | 0.24% | 165 |
|
|
2018
Q1 | – | Sell |
-4,131
| Closed | -$253K | – | 369 |
|
|
2017
Q4 | $253K | Buy |
+4,131
| New | +$258K | 0.19% | 249 |
|
|
2017
Q3 | – | Sell |
-3,888
| Closed | -$217K | – | 358 |
|
|
2017
Q2 | $217K | Buy |
+3,888
| New | +$212K | 0.2% | 233 |
|
|
2016
Q4 | – | Sell |
-5,551
| Closed | -$299K | – | 145 |
|
|
2016
Q3 | $299K | Buy |
+5,551
| New | +$357K | 0.81% | 51 |
|
|
2014
Q2 | – | Sell |
-18,412
| Closed | -$957K | – | 164 |
|
|
2014
Q1 | $957K | Buy |
+18,412
| New | +$980K | 0.39% | 83 |
|
Other funds holding BMY
Campbell & Co Investment Adviser's BMY Position: Q2 2026 in Review
Campbell & Co Investment Adviser reduced its Bristol-Myers Squibb (BMY) stake by 21% in Q2 2026, selling an estimated $350K and leaving 23,327 shares worth $1.34M. The position accounts for 0.07% of the portfolio, ranked #452.
Campbell & Co Investment Adviser first reported a position in BMY in Q1 2014 and has held it in 22 quarters since. The position peaked at $5.81M in Q3 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Campbell & Co Investment Adviser held 23,327 shares of Bristol-Myers Squibb worth $1.34M as of Q2 2026.
- Campbell & Co Investment Adviser sold 6,097 Bristol-Myers Squibb shares in Q2 2026, an estimated $350K.
- Bristol-Myers Squibb made up 0.07% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #452 holding.
- Campbell & Co Investment Adviser first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 22 quarters since.
- Campbell & Co Investment Adviser's Bristol-Myers Squibb position peaked at $5.81M in Q3 2025.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.